NASDAQ:IMMP - Immutep Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $8.50
  • Forecasted Upside: 81.24 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
+0.30 (1.20%)
1 month | 3 months | 12 months
Get New Immutep Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMMP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMMP

Average Price Target: $8.50
▲ +81.24% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Immutep in the last 3 months. The average price target is $8.50, with a high forecast of $9.00 and a low forecast of $8.00. The average price target represents a 81.24% upside from the last price of $4.69.


The current consensus among 2 investment analysts is to buy stock in Immutep. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/10/2021Alliance Global PartnersBoost Price TargetBuy$6.00 ➝ $9.00Low
1/26/2021Alliance Global PartnersBoost Price TargetBuy$5.00 ➝ $6.00Medium
12/14/2020Maxim Group$4.00 ➝ $8.00N/A
11/11/2020Maxim GroupBoost Price TargetPositive ➝ Buy$2.00 ➝ $4.00High
9/22/2020Alliance Global PartnersInitiated CoverageBuyLow
6/2/2020Maxim GroupReiterated RatingBuy$2.00Low
4/30/2020Maxim GroupInitiated CoverageBuy$2.00Low
9/24/2019Maxim GroupReiterated RatingBuy$4.00High
7/31/2019Maxim GroupSet Price TargetBuy$4.00N/A
5/1/2019Maxim GroupReiterated RatingBuy$7.00High
11/27/2018Maxim GroupSet Price TargetBuy$7.00Medium
11/12/2018Maxim GroupReiterated RatingBuy$7.00High
9/28/2018B. RileyInitiated CoverageBuy ➝ Buy$7.75High
5/25/2018Maxim GroupBoost Price TargetPositive ➝ Buy$5.00 ➝ $7.00Low
3/22/2018Maxim GroupInitiated CoverageBuy$5.00Low
3/15/2018Maxim GroupSet Price TargetBuy$5.00Low
2/15/2018Maxim GroupReiterated RatingBuy ➝ Buy$7.00 ➝ $5.00Medium
2/1/2018Maxim GroupReiterated RatingBuy$7.00Low
11/9/2017Maxim GroupReiterated RatingBuy$7.00N/A
8/31/2017Maxim GroupReiterated RatingBuy$7.00Medium
7/19/2017Maxim GroupSet Price TargetBuy$7.00Low
7/10/2017Maxim GroupSet Price TargetBuy$7.00Low
6/27/2017Maxim GroupSet Price TargetBuy$7.00N/A
6/5/2017Maxim GroupSet Price TargetBuy$7.00High
4/19/2017(FBRC)Reiterated RatingBuyHigh
4/6/2017(FBRC)Set Price TargetBuy$6.00Low
2/28/2017HC WainwrightSet Price TargetBuy$8.00N/A
1/24/2017(FBRC)Reiterated RatingBuy$6.00N/A
1/7/2017HC WainwrightReiterated RatingBuy$7.50N/A
12/30/2016Maxim GroupReiterated RatingBuy$16.67 ➝ $7.00N/A
11/15/2016Maxim GroupReiterated RatingBuy$5.00N/A
9/8/2016(FBRC)Set Price TargetBuy$6.00N/A
8/26/2016(FBRC)Reiterated RatingBuyN/A
8/26/2016Roth CapitalReiterated RatingBuy$6.00N/A
7/15/2016(FBRC)Reiterated RatingOutperform$6.00N/A
7/12/2016Maxim GroupReiterated RatingBuy$5.00N/A
6/22/2016Maxim GroupReiterated RatingBuyN/A
6/22/2016HC WainwrightReiterated RatingBuyN/A
6/22/2016(FBRC)Reiterated RatingBuyN/A
(Data available from 6/20/2016 forward)
Immutep logo
Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as Â'eftilagimod alpha' or Â'efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.
Read More

Today's Range

Now: $4.69
Low: $4.69
High: $4.69

50 Day Range

MA: $4.06
Low: $3.18
High: $5.21

52 Week Range

Now: $4.69
Low: $1.03
High: $7.95



Average Volume

1,893,653 shs

Market Capitalization

$338.50 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Immutep?

The following Wall Street sell-side analysts have issued stock ratings on Immutep in the last twelve months: Alliance Global Partners, and Maxim Group.
View the latest analyst ratings for IMMP.

What is the current price target for Immutep?

2 Wall Street analysts have set twelve-month price targets for Immutep in the last year. Their average twelve-month price target is $8.50, suggesting a possible upside of 81.2%. Alliance Global Partners has the highest price target set, predicting IMMP will reach $9.00 in the next twelve months. Maxim Group has the lowest price target set, forecasting a price of $8.00 for Immutep in the next year.
View the latest price targets for IMMP.

What is the current consensus analyst rating for Immutep?

Immutep currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMMP will outperform the market and that investors should add to their positions of Immutep.
View the latest ratings for IMMP.

What other companies compete with Immutep?

How do I contact Immutep's investor relations team?

Immutep's physical mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company's listed phone number is 61-2-8315-7003 and its investor relations email address is [email protected] The official website for Immutep is